Helsestatistik for de nordiske lande 1997 - nomesco

More documents

Recommendations

Info

ORGANIZATION OF HEALTH SERVICES GREENLAND: All pharmaceutical products are distributed through the health service except for certain non-prescribed products which are available to a strictly limited degree from certain shops. Nonprescribed products are distributed to a varying degree by the health service in the districts. FINLAND AND ÅLAND: There are three payment categories, and reimbursement is calculated separately for each purchase and for each refund category. Besides medicines, certain nutrients used in the treatment of a number of diseases as well as ointments used in the treatment of chronic skin diseases are also subsidised. As a main rule, the health insurance scheme fully reimburses the costs exceeding FIM 3,283 in the course of one calendar year. ICELAND: Some pharmaceutical products for the treatment of certain diseases are paid entirely by the health insurance scheme, for other kinds patients pay the full cost themselves. In special individual cases, reimbursement by the health insurance scheme may cover more of the medicine costs than is described above. There is also a reference price system. For generic drugs of the same form, strength and package size, the reimbursement is calculated in relation to the maximum reference price, i.e. the lowest priced generic product. The present reference price list covers about 20 per cent of the registered drugs. 44 GRØNLAND: Al medicin distribueres gennem sundhedsvæsenet, bortset fra håndkøbsmedicin der i stærkt begrænset omfang forhandles fra enkelte dagligvarebutikker. Håndkøbsmedicin udleveres i varierende grad fra sundhedsvæsenet i distrikterne. FINLAND OG ÅLAND: Der er tre betalingskategorier, og refusionen er beregnet separat for hver indkøb og hver kategori. Ud over medicin kan der også gives tilskud til kost for nogle behandlingskrævende sygdomme ligesom til salver ved behandling af kroniske hudsygdomme. Som hovedregel dækker sygeforsikringen de udgifter som overskrider et beløb på 3.283 FIM i løbet af et kalenderår. ISLAND: Lægemidler til behandling af visse sygdomme betales fuldt ud af sygeforsikringen. For andre typer af medicin betaler patienterne selv det fulde beløb. I særlige, individuelle tilfælde kan refusionen fra sygesikringen være højere og egenbetalingen dermed lavere end det fremgår af oversigten. Der findes desuden et referenceprissystem. For synonympræparater med samme form, styrke og forpakning, beregnes tilskuddet i forhold til den maksimale referencepris, forstået som den laveste pris på synonympræparatet. Den nuværende referenceprisliste dækker ca. 20 pct. af de registrerede lægemidler.
NORWAY: Most pharmaceutical products are reimbursed according to a system based on diagnoses and approved products prescribed by a physician. A condition is long-term need for the product, equipment or accessories. SWEDEN: A new rebate system for prescribed pharmaceutical products was introduced in 1997. The rebate is calculated according to the value of the products bought. For purchases of up to SEK 400 over a 12 month period, the user pays all. A rebate is given for exceeding costs. For costs between SEK 400 and 1,200, there is a 50 per cent rebate. Between SEK 1,200 and 2,800 the rebate is 75 per cent, and between SEK 2,800 and 3,800 the rebate is 90 per cent. When products have been purchased for a sum of SEK 3,800, the ceiling of user charge has been reached. At this level, the patient will have paid SEK 1,300 and receives a free pass for the rest of the year. The scheme covers rebate approved medicines on prescription including contraceptives and accessories for stoma. Insulin is free of charge. ORGANIZATION OF HEALTH SERVICES NORGE: De fleste lægemidler refunderes efter et system baseret på diagnoser og godkendte præparater forskrevet af en læge. Udgangspunktet er at man langvarigt har behov for lægemidlet, medicinsk udstyr eller forbrugsvarer. SVERIGE: I 1997 blev der indført et nyt rabatsystem for lægemidler på recept. Rabatten udregnes efter værdien på de lægemidler som købes. For indkøb op til 400 SEK i en 12 måneders periode betaler man selv det hele. På udgifter derudover ydes der rabat. For udgifter mellem 400 SEK og 1.200 SEK gives der 50 pct. rabat. Mellem 1.200 og 2.800 SEK er rabatten 75 pct. og for udgifter mellem 2.800 SEK og 3.800 SEK er rabatten 90 pct. Når der er købt lægemidler for 3.800 SEK har man nået op på egenbetalingens maksimum. Patienten har ved dette niveau selv betalt 1.300 SEK og får så tildelt et frikort for resten af året. Ordningen omfatter rabatberettigede lægemidler på recept, inkl. p-piller og brugsartikler til stomier. Insulin er gratis. Treatment at hospitals Behandlinger ved sygehuse As appears from the survey, there are no user charges for hospitalization in Denmark, the Faroe Islands, Greenland, Iceland and Norway. In Iceland, however, there is a charge for specialist polyclinic treatment at hospitals, cf the section on consultations with physician. FINLAND AND ÅLAND: Patients pay a charge for admission to hospital, psychiatric ward or health centre, which as per January 1 1999 was a maximum of FIM 125 per day. The payment for one Som det fremgår af skemaet er der ingen brugerbetaling for sygehusophold i Danmark, på Færøerne, i Grønland, Island og Norge. Dog betales der i Island for ambulant specialistbehandling ved hospitaler, jvf. afsnittet om lægebesøg. FINLAND OG ÅLAND: Patienterne betaler for indlæggelse på hospital, psykiatrisk afdeling eller sundhedscenter. Pr 1. januar 1999 var den maksimale egenbetaling 125 FIM pr. dag. Betalingen for 45
Page 1 and 2: Health Statistics in the Nordic Cou
Page 3 and 4: Health Statistics in the Nordic Cou
Page 5 and 6: Contents Indhold CONTENTS Preface F
Page 7: CONTENTS SECTION C SEKTION C 209 Ap
Page 10 and 11: DENNE SIDE ER BLANK!
Page 12 and 13: ORGANIZATION OF HEALTH SERVICES CHA
Page 14 and 15: ORGANIZATION OF HEALTH SERVICES Sin
Page 16 and 17: ORGANIZATION OF HEALTH SERVICES tab
Page 18 and 19: ORGANIZATION OF HEALTH SERVICES Cou
Page 20 and 21: ORGANIZATION OF HEALTH SERVICES Alm
Page 22 and 23: ORGANIZATION OF HEALTH SERVICES Per
Page 24 and 25: ORGANIZATION OF HEALTH SERVICES In
Page 26 and 27: ORGANIZATION OF HEALTH SERVICES Gov
Page 28 and 29: ORGANIZATION OF HEALTH SERVICES Loc
Page 30 and 31: ORGANIZATION OF HEALTH SERVICES tri
Page 32 and 33: ORGANIZATION OF HEALTH SERVICES The
Page 36 and 37: ORGANIZATION OF HEALTH SERVICES has
Page 40 and 41: ORGANIZATION OF HEALTH SERVICES Use
Page 42 and 43: ORGANIZATION OF HEALTH SERVICES Rei
Page 46 and 47: ORGANIZATION OF HEALTH SERVICES Use
Page 48 and 49: ORGANIZATION OF HEALTH SERVICES In
Page 50 and 51: ORGANIZATION OF HEALTH SERVICES SWE
Page 52 and 53: ORGANIZATION OF HEALTH SERVICES If
Page 54 and 55: POPULATION AND FERTILITY CHAPTER II
Page 56 and 57: POPULATION AND FERTILITY Figure 2.1
Page 58 and 59: POPULATION AND FERTILITY Table 2.1
Page 64 and 65: POPULATION AND FERTILITY requiremen
Page 74 and 75: CONSUMPTION PATTERNS Table 3.1 Tota
Page 76 and 77: CONSUMPTION PATTERNS Table 3.5 Tota
Page 78 and 79: CONSUMPTION PATTERNS Table 3.9 Sale
Page 80 and 81: MEDICAL TREATMENT, MORBIDITY AND AC
Page 94 and 95:
MEDICAL TREATMENT, MORBIDITY AND AC
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
MORTALITY AND CAUSES OF DEATH been
Page 126 and 127:
MORTALITY AND CAUSES OF DEATH the o
Page 128 and 129:
MORTALITY AND CAUSES OF DEATH Table
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
MORTALITY AND CAUSES OF DEATH Figur
Page 136 and 137:
Page 138 and 139:
RESOURCES ferred from the hospital
Page 140 and 141:
RESOURCES Table 6.2 Health care exp
Page 142 and 143:
RESOURCES Figure 6.1 Health care ex
Page 144 and 145:
RESOURCES Table 6.4 Active health p
Page 146 and 147:
RESOURCES Table 6.6 Active health p
Page 148 and 149:
RESOURCES Table 6.8 Working physici
Page 150 and 151:
RESOURCES Capacity and services at
Page 152 and 153:
RESOURCES Table 6.9 Number of hospi
Page 154 and 155:
RESOURCES Table 6.10 Authorized hos
Page 156 and 157:
RESOURCES Figure 6.5 Average length
Page 158 and 159:
RESOURCES Table 6.13 Bed-days in ho
Page 160 and 161:
RESOURCES C01A, C01D: Cardiac glyco
Page 162 and 163:
RESOURCES R03A, R03B, R03C+R03D, R0
Page 164 and 165:
RESOURCES Table 6.14 Insulins and o
Page 166 and 167:
RESOURCES Table 6.17 Diuretics, bet
Page 168 and 169:
RESOURCES Table 6.19 Psycholeptics
Page 170 and 171:
RESOURCES Table 6.21 Antihistamines
Page 172 and 173:
RESOURCES Table 6.22 … continued
Page 174 and 175:
DENNE SIDE ER BLANK
Page 176 and 177:
CAUSE-OF-DEATH STATISTICS In an int
Page 178 and 179:
CAUSE-OF-DEATH STATISTICS Table 1 C
Page 180 and 181:
CAUSE-OF-DEATH STATISTICS The Nordi
Page 182 and 183:
CAUSE-OF-DEATH STATISTICS 2.1.2 Cau
Page 184 and 185:
CAUSE-OF-DEATH STATISTICS statistic
Page 186 and 187:
CAUSE-OF-DEATH STATISTICS Plans are
Page 188 and 189:
CAUSE-OF-DEATH STATISTICS 2.1.5 Rev
Page 190 and 191:
CAUSE-OF-DEATH STATISTICS 2.2. Clas
Page 192 and 193:
CAUSE-OF-DEATH STATISTICS 2.2.2 Cla
Page 194 and 195:
CAUSE-OF-DEATH STATISTICS Figure 3
Page 196 and 197:
CAUSE-OF-DEATH STATISTICS With auto
Page 198 and 199:
CAUSE-OF-DEATH STATISTICS Statistic
Page 200 and 201:
CAUSE-OF-DEATH STATISTICS the large
Page 202 and 203:
CAUSE-OF-DEATH STATISTICS 2.3. The
Page 204 and 205:
CAUSE-OF-DEATH STATISTICS cause of
Page 206 and 207:
CAUSE-OF-DEATH STATISTICS 2.4. Reso
Page 208 and 209:
CAUSE-OF-DEATH STATISTICS Reference
Page 210 and 211:
APPENDIX 1 Appendix 1 Obstetric def
Page 212 and 213:
APPENDIX 2 Appendix 2 Hospital rela
Page 214 and 215:
APPENDIX 3 Age-adjusted rates (ESP)
Page 216 and 217:
APPENDIX 3 41 Dorsopathies excl. in
Page 218 and 219:
APPENDIX 3 21 Mental and behavioura
Page 220 and 221:
APPENDIX 3 220
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
APPENDIX 5 Appendix 5 Tables on med
Page 228 and 229:
APPENDIX 5 Surgery/Kirurgi General
Page 230 and 231:
FURTHER INFORMATION Further informa
Page 232 and 233:
FURTHER INFORMATION National Board
Page 234 and 235:
FURTHER INFORMATION National Public
Page 236 and 237:
FURTHER INFORMATION National Econom
Page 238 and 239:
FURTHER INFORMATION Norwegian Medic
Page 240 and 241:
NOMESCO PUBLICATIONS 240 NOMESCO Pu
Page 242 and 243:
NOMESCO PUBLICATIONS 28. Health Sta
show all

Helsestatistik for de nordiske lande 1997 - nomesco

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?